Kairos Pharma Ltd. Common Stock (KAPA)
Stock · AMEX · Health Care
$0.6097as of 10/16/2026
Price chart
Active signals
KAPA Signal Track Record
How signals performed across all stocks →What KAPA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 12 | -14.8% | 25% | October 8, 2026 |
| Bollinger Band Breakdown | 5 | -2.5% | 40% | October 1, 2026 |
| Bollinger Band Breakout | 6 | -10.7% | 33% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -2.6% | 25% | October 22, 2025 |
| Any 20-session window (baseline) | -8.1% | 29% |
Computed by MarketWall from daily closing prices since July 3, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KAPA
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1
- Website
- kairospharma.com
Fundamentals
- 1-day range
- $0.6563$0.7315
- Market cap
- $8.35M
- P/E (trailing)
- —
- P/E (forward)
- -0.14
- EPS (trailing)
- $-1.53
- Dividend yield
- —
- Beta
- 3.00
- Avg. volume
- 545.2K
Forecasts
2 analyst ratings
Kairos Pharma Ltd. Common Stock Competitors
Chosen by industry and closest market cap.
- KAPAKairos Pharma Ltd. Common Stock$0.601▼ 10.43%Market cap $8.35MP/E —$0.7108$9.17
- SNGXSoligenix Inc. Common Stock$0.35▼ 2.78%Market cap $8.24MP/E —$0.28$1.76
- TRAWTraws Pharma Inc. Common Stock$0.37▼ 7.50%Market cap $8.21MP/E —$0.391$3.23
- XCURExicure Inc. Common Stock$1.12▲ 0.00%Market cap $8.60MP/E —$0.936$9.48
- ENSCEnsysce Biosciences Inc. Common Stock$0.518▼ 13.38%Market cap $8.06MP/E —$0.23$2.75
- LEXXLexaria Bioscience Corp. Common Stock$2.86▼ 4.35%Market cap $8.82MP/E —$2.43$21.6
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KAPA Kairos Pharma Ltd. Common Stock | $8.35M | — | $0.601 | ▼ 10.43% | $0.7108$9.17 |
| SNGX Soligenix Inc. Common Stock | $8.24M | — | $0.35 | ▼ 2.78% | $0.28$1.76 |
| TRAW Traws Pharma Inc. Common Stock | $8.21M | — | $0.37 | ▼ 7.50% | $0.391$3.23 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.12 | ▲ 0.00% | $0.936$9.48 |
| ENSC Ensysce Biosciences Inc. Common Stock | $8.06M | — | $0.518 | ▼ 13.38% | $0.23$2.75 |
| LEXX Lexaria Bioscience Corp. Common Stock | $8.82M | — | $2.86 | ▼ 4.35% | $2.43$21.6 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- On Thursday, there are stocks with unusual volume. Let's take a look.ChartMill · 10/8/2026
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga · 10/8/2026
- Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.ChartMill · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga · 10/7/2026
- Unusual volume stocks are being observed in Wednesday's session.ChartMill · 10/7/2026
- What's going on in today's sessionChartMill · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 10/7/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 10/7/2026
- Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancerbenzinga · 10/6/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 537.2K
- Total value held
- $293.8K
- Institutional holders
- 10
- Unknown231.9K
- Unknown111.3K
- Unknown44.3K
- Unknown44.3K
- Unknown39.5K
- Unknown24.1K
- Unknown21.6K
- Unknown16.2K
- Unknown4.0K
- Unknown10
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Kairos Pharma Reports Positive Phase 2 Data for ENV-105
Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.
Kairos Pharma Reports Positive Phase 2 Data for ENV-105. Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.